Last reviewed · How we verify
steroid eye drops
Steroid eye drops suppress local ocular inflammation by binding to glucocorticoid receptors and inhibiting inflammatory mediator production.
Steroid eye drops suppress local ocular inflammation by binding to glucocorticoid receptors and inhibiting inflammatory mediator production. Used for Ocular inflammation (post-operative or allergic), Anterior uveitis, Corneal inflammation.
At a glance
| Generic name | steroid eye drops |
|---|---|
| Sponsor | Radboud University Medical Center |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Topical corticosteroids reduce inflammation in the eye by suppressing immune cell activation, decreasing cytokine and prostaglandin production, and stabilizing the blood-ocular barrier. This mechanism provides rapid anti-inflammatory and immunosuppressive effects in ocular tissues, making them effective for inflammatory eye conditions. The Phase 3 formulation from Radboud University likely represents an optimized delivery or novel steroid compound for improved efficacy or safety in ocular use.
Approved indications
- Ocular inflammation (post-operative or allergic)
- Anterior uveitis
- Corneal inflammation
Common side effects
- Elevated intraocular pressure
- Cataract formation (with prolonged use)
- Local irritation or discomfort
- Secondary infection risk
Key clinical trials
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (PHASE2)
- FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial (PHASE3)
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (PHASE1, PHASE2)
- Visual and Patient-Reported Outcomes After Bilateral Non-Diffractive EDOF IOL Implantation (NA)
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |